DEVELOPMENT AND VALIDATION OF DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR ESTIMATION OF ATORVASTATIN CALCIUM AND AMLODIPINE BESYLATE IN TABLET DOSAGE FORM
ABSTRACT Atorvastatin calcium (AT) is hypolipidemic agent and Amlodipine besylate (AM) is calcium channel blocker. The combination of both drugs is used in treatment of hypertension. The present communication deals with development of simple, sensitive, rapid and economical method for simultaneous estimation of atorvastatin calcium and amlodipine besylate in combined dosage form. The AT and AM stock solutions are prepared in (50:50 V/V) methanol: water. The method of analysis is derivative spectroscopy to eliminate spectral interference by measuring absorbances at 241nm and 250 nm for AM and AT respectively. The AT and AM are linear in concentration range of 0-14 µg/ml and 0-7 µg/ml respectively. The limit of detection (LOD) and limit of quantitation (LOQ) of AM was 0.29 and 0.75 µg respectively. The limit of detection (LOD) and limit of quantitation (LOQ) of AT was 0.21 and 0.60 µg respectively. The results of analysis were validated by ICH Q2B (R1). The results of recovery studies and precision were found to be within limits. INTRODUCTION Atorvastatin calcium (AT)[ (ßR,dS)-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4[(phenylamino) carbonyl]-1H-pyrrole-1-heptenoic acid calcium salt is a hypolipidemic agent, which inhibits HMG CO-A reductase, enzyme involved in lipid synthesis 1 Amlodipine besylate (AM), [3-ethyl-5-methyl (4RS)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-methyl-1-dihydropyridine-3, 5-dicarboxylate benzenesulphonate is a calcium channel blocker, used in hypertension treatment. Both are official in BP and EP
- SourceAvailable from: Asmaa Ahmed El-Zaher[Show abstract] [Hide abstract]
ABSTRACT: Caduet tablets are novel prescription drug that combines amlodipine besylate (AM) with atorvastatin calcium (AT). A spectrofluorimetric and an HPLC-fluorescence detection methods were developed for simultaneous determination of both drugs in tablets. In the spectrofluorimetric method, native fluorescence of AM and AT were measured in methanol at 442 and 369 nm upon excitation at 361 and 274 nm, respectively. The emission spectrum of each drug reveals zero value at the emission wavelength of the other drug, thus allowing their simultaneous determination without interference. In the HPLC method, separation of AM and AT was achieved within 8 minutes on a C18 column using acetonitrile:phosphate buffer (0.015 M, pH 3) (45:55, v/v) as the mobile phase. Fluorescence detection was carried out using excitation wavelengths 361 and 274 nm and emission wavelengths 442 and 378 nm for AM and AT, respectively. Excellent linearity was observed. Careful validation proved advantages of the new methods: high sensitivity, accuracy, selectivity and suitability for quality control laboratories.Analytical Chemistry Insights 01/2013; 8:107-15.
- [Show abstract] [Hide abstract]
ABSTRACT: Two simple, accurate, precise, reproducible UV Spectrophotometric methods have been developed for the simultaneous estimation of Amlodipine Besylate and Indapamide in tablet dosage form. First method employed was Absorption Correction Method which involves direct estimation of Amlodipine Besylate at 360 nm, as at this wavelength Indapamide has zero absorbance and shows no interference. For estimation of Indapamide, corrected absorbance was calculated at 242 nm due to the interference of Amlodipine Besylate at this wavelength. The second method was first order derivative spectrophotometry, wavelengths selected for quantitation were 242 nm for Amlodipine Besylate (zero crossing point for Indapamide) and 238 nm for Indapamide (zero crossing point for Amlodipine Besylate). In both methods linearity was observed in the concentration range of 10-70 μg/ml for Amlodipine Besylate and 2-16 μg/ml for Indapamide.The results of analysis have been validated statistically and by recovery studies. The proposed method was successfully applied for the simultaneous estimation of both drugs in commercial tablet dosage form.International Journal of PharmTech Research 08/2012; 4(3):974-4304.
DEVELOPMENT AND VALIDATION OF DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR
ESTIMATION OF ATORVASTATIN CALCIUM AND AMLODIPINE BESYLATE IN TABLET
SMITA T. KUMBHAR, SWAPNIL D. JADHAV, NEELA M. BHATIA AND MANISH S. BHATIA*
Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, Kolhapur-416013(M.S.) India.
Received: 9 May 2011, Revised and Accepted: 21 June 2011
Atorvastatin calcium (AT) is hypolipidemic agent and Amlodipine besylate (AM) is calcium channel blocker. The combination of both drugs is used
in treatment of hypertension. The present communication deals with development of simple, sensitive, rapid and economical method for
simultaneous estimation of atorvastatin calcium and amlodipine besylate in combined dosage form. The AT and AM stock solutions are prepared in
(50:50 V/V) methanol: water. The method of analysis is derivative spectroscopy to eliminate spectral interference by measuring absorbances at
241nm and 250 nm for AM and AT respectively. The AT and AM are linear in concentration range of 0-14 µg/ml and 0-7 µg/ml respectively. The
limit of detection (LOD) and limit of quantitation (LOQ) of AM was 0.29 and 0.75 µg respectively. The limit of detection (LOD) and limit of
quantitation (LOQ) of AT was 0.21 and 0.60 µg respectively. The results of analysis were validated by ICH Q2B (R1). The results of recovery studies
and precision were found to be within limits.
Keywords: UV Spectrophotometry, Amlodipine, Atorvastatin, Derivative Spectrophotometry
Atorvastatin calcium ( AT )[ (ßR,dS)-2-( 4-fluorophenyl )- β,δ-
hypolipidemic agent, which inhibits HMG CO-A reductase,
enzyme involved in lipid synthesis1
salt acid calcium is a
Amlodipine besylate (AM), [3-ethyl-5-methyl (4RS)-2-[(2-
dihydropyridine-3, 5-dicarboxylate benzenesulphonate is a
calcium channel blocker, used in hypertension treatment. Both
are official in BP and EP
Several spectrophotometric and chromatographic methods
methods are reported for estimation of AT single drug or in
combination with other
spectrophotometric and chromatographic methods are reported
to estimate AM as single drug or in combination with other
drugs8-13. For simultaneous estimation of AT and AM, HPLC,
simultaneous equation, dual wavelength method are reported14-
. But derivative spectrophotometric method is not reported
which is simple, precise and accurate.
4-7. A number of
MATERIALS AND METHODS
Chemicals: AT and AM were procured from Hetero Drugs
Limited, (H.P.) as gift sample. Methanol AR grade (Merck Pvt.
Ltd.) was used for analysis. The distilled water was prepared
using glass distillation assembly in laboratory.
Instrument: Spectrophotometric analysis was carried out on
JASCO model V- 530 UV-Visible double beam high speed scanning
spectrophotometer with a single monochromator with a 1200
grooves/mm concave grating. Detector was silicon photodiode
(S1337). Light source used were deuterium lamp (190 to 350
nm) and halogen lamp (330 to 1100 nm).The instrument is
having wavelength accuracy of ± 0.3 nm and baseline stability of
± 0.001 Abs. / Hrs.
Preparation of standard stock solutions
Standard stock solutions of AT and AM were prepared by
dissolving 10 mg each in 25 ml of (50:50 V/V) methanol:water
solvent mixture separately in 100 ml volumetric flask and finally
making up the volume up to the mark with same solvent system.
The concentration of stock solutions of both drugs is 1000 µg/ml.
The required solutions are prepared by diluting these solutions.
Selection of wavelength for analysis
These standard stock solutions were further diluted to get final
dilutions containing 10 µg/ml of AT and AM each10. These
dilutions were scanned in UV region (400-200nm). The obtained
individual spectra were overlain (Fig 1). This overlain zero order
spectrum was then converted to first order derivative spectrum
(Fig 2). From derivative spectrum, wavelength of 241nm and 250
nm for AT and AM were selected as estimation wavelengths,
respectively to avoid interference of each other at respective
Linearity study of AT and AM
Using standard stock solutions of both drugs, seven mixed
standard solutions were prepared containing 0µg/ml and 7
µg/ml, 2 µg/ml and 6 µg/ml, 5 µg/ml and 4 µg/ml, 4 µg/ml and 6
µg/ml, 3 µg/ml and 8 µg/ml, 2 µg/ml and 10 µg/ml, 1 µg/ml and
12 µg/ml, 0 µg/ml and 14 µg/ml of AT and AM respectively20
mixed standard solutions were scanned over 400-200nm and
derivatised to measure substantial absorbance at 241 for AT and
at 250 for AM respectively. Calibration curves for both drugs
were plotted using absorbance values and concentrations of each
drug in the mixed standard solutions. It was found that
atorvastatin calcium is linear in concentration range of 0- 14
µg/ml with correlation coefficient of 0.9994 while that of
amlodipine besylate is linear in concentration range of 0- 7 µg/ml
with correlation coefficient of 0.9992.
Analysis of marketed formulation
The commercial formulation ZIVAST AM (Hetero Drugs Limited)
was purchased from local pharmacy. The average weight of each
tablet (before and after removing coat) was calculated using 20
tablets. The twenty tablets were powdered finely in glass mortar
after removing coatings. The powdered sample equivalent to
10mg of AT (5 mg AM) was taken in 30 ml methanol: water
solvent mixture, shaken well to dissolve drugs and transferred
quantitatively to 100 ml volumetric flask after filtering through
Whatman filter paper twice. Finally volume was made up. Three
solutions were prepared from this stock solution of tablet
covering entire calibration range. These solutions were further
diluted so that final dilutions will lie in workable limit of 0-
14µg/ml for AT and 0-7 µg/ml for AM. The absorbance values of
both drugs were recorded at respective wavelength present in
derivatised spectra of drugs. The concentrations of both drugs
were calculated using calibration curve data. The results of tablet
analysis are reported in Table 1.
International Journal of Pharmacy and Pharmaceutical Sciences
ISSN- 0975-1491 Vol 3, Suppl 4, 2011
A A A Ac c c ca a a ad d d de e e em m
m mi i i ic c c c S S S Sc c c ci i i ie e e en n n nc c c ce e e es s s s
Bhatia et al.
Int J Pharm Pharm Sci, Vol 3, Suppl 4, 195-197
RESULT AND DISCUSSION
The combination of AT and AM is used in treatment of
hypertension. Hence it is necessary to develop method for
simultaneous estimation of AT and AM. Previously reported
spectrophotometric methods were found to be less sensitive and
selective for estimation of both drugs.
In present communication we have succeeded in development
and validation of simple, accurate, precise, sensitive and selective
estimation of both drugs form tablet formulations.
method for simultaneous
The method was validated according to ICH Q2B (R1) guidelines,
meant for validation of analytical methods to check accuracy,
precision, linearity range, limit of detection, limit of
quantification and specificity.
Accuracy: Recovery studies were performed by standard addition
method at three levels i.e., 80%, 100% and 120%. The known
amounts of standard AT and AM were added to pre-analyzed
laboratory samples and they were subjected to analysis by the
proposed method. Results of recovery studies are shown in Table
1. The results of recovery studies were found to be in range of
98.43 to 101.47 with standard deviation value of 1.765.
Precision: Precision study was performed to find out intra-day
and inter-day variations. The results of precision studies are
reported in Table 2 and values of standard deviation less than 2%
indicates high degree of precision.
Limit of detection (LOD) and limit of quantitation (LOQ); The LOD
and LOQ were separately determined based on the calibration
curves. The standard deviation of the y-intercepts and slope of
the regression lines were used for calculation. The AT and AM are
linear in concentration range of 0-14 µg/ml and 0-7 µg/ml
The LOD and LOQ of AM was 0.29 and 0.75 µg respectively.
The LOD and LOQ of AT was 0.21 and 0.60 µg respectively.
Table 1: Result of Tablet Analysis and Recovery Studies
Label Claim (mg/ tablet)
% Amount Founda ± R.S.D.
100.06 ± 0.8859
99.59 ± 0.5019
99.72 ± 0.5074
99.21 ± 1.0107
99.59 ± 0.5019
98.37 ± 0.7846
99.72 ± 0.5074
99.45 ± 0.5277
100.04 ± 0.3240
100.45 ± 0.8539
a ± R.S.D.b
a: Average of Three Determinations, b: Relative Standard Deviation
Table 2: Result of Precision Studies
% Label claim Estimateda
98.98 ± 1.342
100.04 ± 1.2422
99.40 ± 1.2844
a: Average of Nine Determinations, b: Relative Standard Deviation
Fig. 1: Overlain Spectra of AT and AM in Zero Order Derivative Mode
Bhatia et al.
Int J Pharm Pharm Sci, Vol 3, Suppl 4, 195-197
Fig. 2: Overlain Spectra of AT and AM in First Order Derivative Mode
The proposed derivative spectrophotometric method is found to
be accurate, precise, economic and rapid for simultaneous
estimation of AT and AM. It satisfactorily eliminates interference
from excipients. Hence it can be employed for routine analysis of
both drugs in marketed formulations in quality control
The authors are thankful Principal, Bharati Vidyapeeth College of
Pharmacy, Kolhapur for providing facilities and to Hetero Drugs
Limited, Himachal Pradesh for providing gift sample of drugs AT
and AM for this research project.
Moffat AC, Osselton MD, Widdop B Clarke’s Analysis of
Drugs and Poisons in Pharmaceuticals; Body Fluids and
Postmortem Material, 3rd ed. Pharmaceutical Press,
London; 2004. p. 654.
British Pharmacopoeia, Vol.1, London: Her Majesty’s
Stationary Office; 2004. p.125, 149.
European Directorate for the Quality of Medicine Council of
Europe, European Pharmacopoeia, 4th ed. Stransburg, cedex
1, France; 2002. p.639, 657.
Manoj K, Shanmugapandiyan P, Anbazhagan S RP-HPLC
Method for Simultaneous Estimation of Atorvastatin
Calcium and Aspirin from Capsule Formulation. Indian
Drugs 2004; 41:284-288.
Saravanamuthukumar M, Palanivelu M, Anandarajagopal K,
Sridharan D Simultaneous Estimation and Validation of
Atorvastatin Calcium And Ubidecarenone (Coenzyme Q10)
in Combined Tablet Dosage Form by RP-HPLC Method. Int J
Pharmacy and Pharm Sci 2010;2(2):36-38.
Joseph L, George M, Venkata Ranga Rao B Simultaneous
Estimation of Atorvastatin and Ramipril by RP-HPLC and
Spectroscopy. Pak. J Pharm Sci 2008; 21(3): 282-284.
Novakova L, Satinsky D, Solich P HPLC Methods for
Determination of Simvastatin and Atorvastatin. Trends in
Analytical Chemistry 2008; 27(4):352-367.
Rao JR, Kadam SS, Mahadik KR RP-HPLC Determinations of
Amlodipine and Benazepril Hydrochloride in Tablets. Indian
Drugs 2002; 39:378.
Jain HK, Agrawal RK Spectrophotometric Method for
Simultaneous Estimation of Amlodipine Besylate and
Lisinopril in Tablets. Indian Drugs 2003; 37:1906.
10. Mishra P, Shah K, Gupta A Spectrophotometric Methods for
Simultaneous Estimation of Nebivolol Hydrochloride and
Amlodipine Besylate in Tablets. Int J Pharmacy and Pharm
Sci 2009; 2(1): 55-61.
11. Prabhakar AH, Giridhar
Determination of Amlodipine Besylate in Pure Form and in
Tablets. Indian Drugs 2002; 39:204.
12. Surekha A, Khopade, Jain NK Difference Spectrophotometric
Estimation of Amlodipine Besylate. Indian Drugs 2000;
13. Gohil K, Trivedi P, Molvi KJ Spectrophotometric Method for
Amlodipine Besylate in Bulk and in Tablet Dosage Forms.
Indian J Pharm Sci 2005; 67:376.
14. Mishra P, Gupta A, Shah K Simultaneous Estimation of
Atorvastatin Calcium and Amlodipine Besylate from Tablets.
Indian J Pharm Sci 2007; 69(6): 831-833.
15. Shah DA, Bhatt KK, Shankar MB, Mehta RS, Gandhi TR,
Baldania SL RP- HPLC Determination of Amlodipine
Besylate and Atorvastatin Calcium Combination in Tablets.
Indian J Pharm Sci 2006; 68(6): 796-799.
16. Rajeshwari KR, Sankar GG, Rao AL, Shesagirirao JVLN RP-
HPLC Method for Simultaneous
Amlodipine Besylate and Atorvastatin Calcium in Tablet
Dosage Form Indian J Pharm Sci 2006; 68(2): 275-277.
17. Khan MR, Jain D Simultaneous Spectrophotometric
Determination of Atorvastatin Calcium and Amlodipine
Besylate in Tablets. Indian J Pharm Sci 2007; 68(4):546-548.
18. Sahu R, Patel VB Simultaneous Spectrophotometric
Estimation of Amlodipine Besylate and Atorvastatin Calcium
in Binary Mixture. Indian J Pharm Sci 2007; 69(1): 110-111.
19. Sethi PD, Quantitative Analysis of Drug in Pharmaceutical
Formulation, 3rd ed. New Delhi: CBS Publishers and
Distributors; 1997. p.373.
20. Pillai S, Singhvi I Spectrophotometric Simultaneous
Estimation of Ranitidine Hydrochloride and Ondansetran
Hydrochloride from Tablet Formulations Indian J Pharm Sci
21. International Conference on Harmonization, Draft Revised
Guidance on Validation
Methodology. Federal Register 2000; Q2B (R1) 62: 27464.
of Analytical Procedures: